Dr. Shebuski has more than 30 years of experience in the pharmaceutical industry, specializing in drug discovery and development. Currently, Dr. Shebuski is Vice President of Pharmaceutical Research and Development of InspiRx Pharmaceuticals in Durham, NC. He is also co-founder, President and CEO of Cylerus, Inc., which is developing novel drug delivery technology to prolong the survival of prosthetic vascular grafts, particularly for patients requiring chronic hemodialysis. As well as founding and managing biotech startup companies, Dr. Shebuski currently consults for small, mid-size and large pharmaceutical companies on pharmacology and biotech. Previously, as Director of the Cardiovascular Therapeutics group at Pharmacia & Upjohn, he managed the team responsible for FDA approval of a Class III anti-arrhythmic agent. Dr. Shebuski also served as the Senior Scientist responsible for leading cardiovascular drug discovery teams at Merck Research Laboratories and Smith Kline & French. He was appointed an advisor in the CardioRenal Division of the Center for Drug Evaluation and Research. As an expert witness, Dr. Shebuski specializes in intellectual property cases, and is an expert in FDA regulations.


  • PhD, Pharmacology, University of Minnesota-Minneapolis, 1985
  • BS, Microbiology, University of Wisconsin-Madison, 1976


  • American Association for the Advancement of Science, Member 
  • American Heart Association, Member
  • American Society for Pharmacology and Experimental Therapeutics, Member
  • New York Academy of Sciences, Member 
  • Thrombosis Council, American Heart Association, Member 
  • 1st Annual F.E. Shideman Distinguished Alumnus Award, University of Minnesota, Department of Pharmacology, 1994
  • Bacaner Basic Science Research Award for Outstanding Graduate Research in Pharmacology, University of Minnesota, 1985 
  • Travel Award, Graduate Student, American Society for Pharmacology and Experimental Therapeutics, Annual Meeting, 1984 

* Partial bio; contact Humatec for comprehensive CV